Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 DiabetesAngeliki Meritsi, Anastasia Thanopoulou, Dimitrios Pektasides et al.|Clinical Diabetes|2022Cited by 6
Addition of Dulaglutide or Empagliflozin to Standard-of-Care Treatment: Effect on Liver Steatosis in Patients With Type 2 Diabetes MellitusEmmanouil Koullias, John Koskinas, Maria Papavdi et al.|Cureus|2024Cited by 4
Blood based biomarkers as non-invasive screening tools for hepatic fibrosis in subjects with Type 2 Diabetes MellitusAngeliki Meritsi, Anastasia Thanopoulou, Dimitra Latsou et al.|Metabolism|2022Cited by 1
Association of PNPLA3 and TM6SF2 Polymorphisms with NAFLD in Greek People with Type 2 Diabetes MellitusAngeliki Meritsi, Anastasia Thanopoulou, Dimitra Latsou et al.|Metabolism|2023Cited by 0
Association of TM6SF2 (E167K) with NAFLD in adult Greek people with Type 2 Diabetes Mellitus (T2DM)Angeliki Meritsi, Anastasia Thanopoulou, Stamatia Rapti et al.|Research Square|2024Cited by 0